DAXOR CORP 10-Q Summary: Period Ended September 30, 2000
Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 2000, for DAXOR Corporation. The company operates in the medical technology sector, focusing on blood volume analysis (BVA-100) and localized semen and blood banking services. The company is transitioning its revenue model to rely more heavily on equipment and kit sales, currently initiating distribution networks.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2000 | 9 Months Ended Sep 30, 1999 |
|---|---|---|
| Total Revenues | $2,174,599 | $2,248,424 |
| Operating Revenues | $529,208 | $433,557 |
| Net Income | $98,585 | $154,552 |
| Net Income Per Share | $0.02 | $0.03 |
| Cash Flow from Operations | ($38,213) | ($303,841) |
| Total Assets | $46,576,584 | $35,846,065 |
| Total Liabilities | $9,766,529 | $6,566,496 |
| Shareholders' Equity | $36,810,055 | $29,279,569 |
| Loans Payable | $1,756,122 | $2,443,794 |
| Marketable Securities (Fair Value) | $45,769,669 | $34,867,286 |
Material Changes vs. Prior Period
- Revenue Composition: While total revenues decreased slightly year-over-year, operating revenues increased by approximately 22% ($529,208 vs. $433,557), driven by BVA-100 operations. This growth was partially offset by a significant decline in capital gains from the sale of securities ($184,243 in 2000 vs. $388,117 in 1999).
- Profitability: Net income before taxes declined to $112,331 from $157,064 in the prior year, primarily due to lower investment gains and increased interest expense ($157,567 vs. $99,837).
- Balance Sheet Strength: Total assets increased by over $10 million, largely due to a rise in the fair value of marketable securities. Net unrealized holding gains on securities increased to $23.3 million (pre-tax), contributing significantly to shareholders' equity.
- Liquidity: Cash and cash equivalents decreased from $67,783 to $19,067. However, cash flow from operations improved significantly, moving from a use of $303,841 in 1999 to a use of only $38,213 in 2000.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management anticipates that sales of equipment and kits will become the major income source. The company is evaluating options for a nationwide sales force versus independent dealer networks.
- Reimbursement: Medicare has established a specific code for the Volumex kit Albumin I-131, which should facilitate hospital reimbursement for blood volume measurements.
- Capital Strategy: The company is evaluating the acquisition of additional capital to accelerate national and international marketing. Current reserves are being used for marketing the Blood Volume Analyzer and sustaining banking services.
- Debt Structure: The company holds short-term loans totaling $1.76 million, secured by marketable securities. This includes a $1 million bank loan and $756,122 in margin debt due to brokers.
- Risks: The "instrument loaner reagent plan" results in a slower return on capital expenditure compared to direct sales or leases. The company relies heavily on its investment portfolio for asset value, which is subject to market volatility.
Investor Verification Checklist
- Verify the sustainability of operating revenue growth from the BVA-100 given the decline in investment-related income.
- Assess the risk exposure associated with $1.76 million in loans secured by the company's marketable securities portfolio.
- Confirm the timeline and success of the new distribution networks and the impact of the new Medicare reimbursement code on sales velocity.
- Monitor cash burn rates, as operating cash flow remains negative despite improvements, and cash on hand is low ($19,067).
- Review the company's plan for raising additional capital to fund the proposed national marketing expansion.